I
IR BioSciences Holdings Inc. Stock Analysis IRBS
IR Biosciences Holdings, Inc. operates as a development stage biotechnology company. The company is headquartered in Scottsdale, Arizona and currently employs 4 full-time employees. The company went IPO on 2000-01-31. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The firm focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.
Read More IR BioSciences Holdings Inc (IRBS) Chart
Financial Metrics & Statements of IR BioSciences Holdings Inc (IRBS)
FAQ's for IR BioSciences Holdings Inc (IRBS)
- According to Musaffa’s Shariah screening methodology, IR BioSciences Holdings Inc (IRBS) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.